Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...

Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation ...

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 11,320,000 ...

2024 marks the sixth consecutive year production guidance has been achieved Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX ...

Benjamin J. Hindson, the See Remarks of $TXG, sold 4,573 shares of the company on 02-24-2025 for an estimated $50,602. We received data on the trade from a recent SEC ...

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

ALAN MATEO, a director at $TXG, bought 40,000 shares of the company on 02-21-2025 for an estimated $445,572. This trade was reported by Quiver Quantitative using data ...

National Bank Financial reduced their FY2025 earnings per share (EPS) estimates for Torex Gold Resources in a note issued to ...

Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...